| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(7 years from now) | |
Vesicare Ls is owned by Astellas.
Vesicare Ls contains Solifenacin Succinate.
Vesicare Ls has a total of 1 drug patent out of which 0 drug patents have expired.
Vesicare Ls was authorised for market use on 26 May, 2020.
Vesicare Ls is available in suspension;oral dosage forms.
The generics of Vesicare Ls are possible to be released after 18 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 26, 2023 |
| Pediatric Exclusivity (PED) | Nov 26, 2023 |
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
How can I launch a generic of VESICARE LS before it's drug patent expiration?
More Information on Dosage
VESICARE LS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic